Zevalin Related Clinical Trials
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma [Active, not recruiting]
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma [Active, not recruiting]
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma [Completed]
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma [Completed]
Autologous Stem Cell Transplantation (ASCT) With Zevalin Plus BuCyE in B-Cell Non-Hodgkin's Lymphoma (NHL) [Active, not recruiting]
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas [Active, not recruiting]
Zevalin® First Line in Follicular Lymphoma [Recruiting]
Study Of Yttrium-Ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma [Active, not recruiting]
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma [Not yet recruiting]
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-Based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) [Recruiting]
Ibritumomab Tiuxetan for Early Stage Indolent Lymphomas [Recruiting]
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies [Recruiting]
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma [Recruiting]
Zevalin and BEAM High-Dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin’s Lymphoma [Not yet recruiting]
Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance [Recruiting]
A Study of Zevalin and Simultaneous Application of BEAM High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas [Recruiting]
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma [Terminated]
Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R [Recruiting]
HD Therapy and Radioimmunotherapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma [Recruiting]
Zevalin-Beam for Aggressive Lymphoma [Recruiting]
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL [Recruiting]
Allogenic Stem Cell Transplantation (SCT) With Non-Myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) [Recruiting]
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-Cell Difusse Lymphom [Recruiting]
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma [Recruiting]
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-Cell Lymphoma After 6 Cycles of CHOP [Recruiting]
Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma [Recruiting]
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation [Recruiting]
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma [Completed]
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®) [Not yet recruiting]
Fludarabine Plus Cyclophosphamide Followed by Zevalin in Non-Follicular Indolent Lymphomas Refractory or Relapsed [Recruiting]
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia [Completed]
CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment [Active, not recruiting]
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma [Recruiting]
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma [Active, not recruiting]
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Recruiting]
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen [Withdrawn]
Safety Study to Evaluate Induction and Consolidation Treatment Combination in Mantle Cell Lymphoma Patients [Recruiting]
Efficacy and Safety of Treatment With a Single Dose of 90Y-Ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL [Withdrawn]
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma [Recruiting]
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma [Active, not recruiting]
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL [Completed]
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma [Recruiting]
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment [Recruiting]
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma [Recruiting]
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma [Recruiting]
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma [Recruiting]
Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage II, Stage III, or Stage IV Relapsed or Refractory Non-Hodgkin's Lymphoma [Suspended]
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma [Recruiting]
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma [Completed]
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder [Completed]
Targeted Intensification Utilizing ZBEAM Followed by Autologous Stem Cell Transplantation (ASCT) in Patients With High-Grade B-Cell Lymphoma [Recruiting]
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma [Completed]
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma [Recruiting]
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma [Withdrawn]
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma [Recruiting]
Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma [Recruiting]
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma [Completed]
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma [Active, not recruiting]
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma [Recruiting]
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma [Completed]
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma [Recruiting]
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma [Recruiting]
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [No longer recruiting]
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [No longer recruiting]
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma [Recruiting]
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation [Completed]
Yttrium Y 90 Ibritumomab Tiuxetan With or Without Rituximab, Combination Chemotherapy, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma [Recruiting]
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma [Recruiting]
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma [Recruiting]
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]
Radioimmunotherapy With 90Y-Ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma [Recruiting]
High Dose, Absorbed Dose Adjusted 90Y-Ibritumomab With PBSC Support in B-Cell Lymphoma [Recruiting]
|
